amneal enter ten-year agreement jerom steven pharmaceut
jsp give distribut right jsp gener form levothyroxin sodium
tablet abil push lannett rate pictur provid boost
long-term ebitda though product flag sourc
upsid refer note detail two question mark
give us paus gener levothyroxin competit landscap evolv
even contribut gener get aspir
ebitda target around vs ebitda guidanc
mind share ebitda difficult us get
construct reiter neutral rate rais pt
push lannett pictur agreement levothyroxin
gener go effect follow expiri jsp current agreement
recal gener ab-rat unithroid alreadi distribut
per exist agreement jsp gain brand via acquisit gemini
earlier year annual sale brand north prescript rx
show year-to-d annual growth rate per iqvia though
disclos specif econom agreement includ up-front payment
profit share connect follow announc compani
suggest margin inclus profit share somewhat lower
corpor margin guid corpor gross margin
lower margin product given secur agreement
jsp competit process given plan addit
competit key wild card regard gener levothyroxin sale
levothyroxin gener distribut annual near per iqvia
product current account rx written levothyroxin sodium
tablet inclus brand gener levothyroxin one complex
oral solid avail narrow therapeut window rel
static competit landscap term number particip unlik chang
dramat mean gener compani tri enter
market cite lupin potenti nearer-term entrant surmis singl
entrant impact price volum natur levothyroxin
mean patient stabl dose wari switch even second
new entrant unlik big impact volum view said evolv
competit dynam even context entrant higher-
margin oral solid clearli major implic price dynam
make difficult handicap long-term ebitda impact agreement
price competit risk gener product
amneal focus primarili gener market
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
consensu
repres contribut gener levothyroxin sodium begin late
compani report factset pjc estim
rais pt
new pt base price-to-earnings ep estim
discount unchang two year unchang pt
reflect somewhat higher multipl given contribut levothyroxin gener
view enhanc credibl part manag new given execut
agreement said believ manag long-term ebitda target
around aggress manag guid ebitda
reflect signific impact new approv significantli greater price
stabil share trade ebitda believ
essenti reflect aggress long-term expect new pt impli
ebitda mid-point guidanc rang sensibl multipl nonetheless
premium major gener compani name teva
context gener space myriad uncertainti rhetor surround greater
price stabil late notwithstand
page
million except per brand sale brand gener administr tax share amneal quarterli annual incom statement
million except ep
zomig brand sale
sale
sell gener administr
patent litig
incom loss tax
item net tax
expens revenu
sell gener administr
sell gener administr
ipxl began provid individu brand product sale earlier reflect pjc estim corepharma includ albenza emverm model reflect impact albenza gener competit start late
exclud cost relat remedi effort hayward ca manufactur facil
follow complet merger ameanl provid pro forma financi valu may reflect pjc estim
financi prior reflect legaci ipxl begin sale reflect amneal legaci ipxl sale
acquir part amneal acquisit gemini reflect pjc estim report net sale product
proprietari piper jaffray co august
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
